At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?-Reference-Cited by-同舟云学术

At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?

Published:2020-06-27 Issue:5 Volume:8 Page:1304-1311
ISSN:2047-2919
Container-title:Andrology
language:en
Short-container-title:Andrologia

Author:

Harvey Neil¹^ORCID,Pearce Ian²

Affiliation:

1. Urology Department Stepping Hill Hospital Stockport NHS Foundation Trust Poplar Grove UK

2. Urology Department Manchester Royal Infirmary Manchester University Hospitals Foundation Trust Manchester UK

Publisher

Wiley

Subject

Urology,Endocrinology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/andr.12830

Reference60 articles.

1. Francois de LaPeyronie (1678-1747): the man and the disease he described

2. Peyronie’s Disease: AUA Guideline

3. Medical Treatments of Peyronie's Disease: Past, Present, and Future

4. The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market

5. Actelion Pharmaceuticals Pty Ltd.XIAFLEX® (Collagenase Clostridium Histolyticum) Product Discontinuation from 28 June 2019. n.d.https://www.medsafe.govt.nz/safety/DHCPLetters/XiaflexDiscontinuation.pdf. Accessed 17 December 2019.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis;International Journal of Impotence Research;2023-08-25

2. Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis;2023-05-09

3. BIM Visual Programming Tools Applications in Infrastructure Projects: A State-of-the-Art Review;Applied Sciences;2021-09-08

4. Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease and the impact of its discontinuation;International Journal of Impotence Research;2021-07-15